This HTML5 document contains 44 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n11http://linked.opendata.cz/resource/drugbank/drug/DB05659/identifier/pubchem-substance/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB05659/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB05659/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB05659/identifier/pubchem-compound/

Statements

Subject Item
n2:DB05659
rdf:type
n3:Drug
n3:description
Faropenem medoxomil is an ester prodrug derivative of the beta-lactam antibiotic faropenem. The prodrug form of faropenem offers dramatically improved oral bioavailability and leads to higher systemic concentrations of the drug. Faropenem medoxomil is a broad-spectrum antibiotic that is highly resistant to beta-lactamase degradation. It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc.
n3:generalReferences
# Gettig JP, Crank CW, Philbrick AH: Faropenem medoxomil. Ann Pharmacother. 2008 Jan;42(1):80-90. Epub 2007 Dec 19. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18094341 # Schurek KN, Wiebe R, Karlowsky JA, Rubinstein E, Hoban DJ, Zhanel GG: Faropenem: review of a new oral penem. Expert Rev Anti Infect Ther. 2007 Apr;5(2):185-98. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17402834
n3:group
investigational
n3:indication
Investigated for use/treatment in bacterial infection, bronchitis, otitis media, and pediatric indications.
owl:sameAs
n6:DB05659
dcterms:title
faropenem medoxomil
adms:identifier
n8:DB05659 n9:6918218 n10:5293428 n11:12014697
n3:mechanismOfAction
Like other beta-lactam antibiotics, faropenem acts by inhibiting the synthesis of bacterial cell walls. It inhibits cross-linkage between the linear peptidoglycan polymer chains that make up a major component of the cell wall of Gram-positive bacteria. It does this by binding to and competitively inhibiting the transpeptidase enzyme used by bacteria to cross-link the peptide (D-alanyl-alanine) used in peptidogylcan synthesis.
n3:synonym
Faropenem daloxate SUN-A0026 SUN-208
n3:IUPAC-Name
n4:271B45DD-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B45E3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B45E2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B45DF-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B45E0-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B45E1-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B45DB-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B45DC-363D-11E5-9242-09173F13E4C5 n4:271B45D9-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B45DA-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B45E9-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B45EA-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B45E4-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B45E5-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B45E7-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B45E6-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B45E8-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Gram-positive Bacteria
n3:casRegistryNumber
141702-36-5
n3:category
n3:Bioavailability
n4:271B45EF-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B45F1-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B45F2-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B45EE-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B45ED-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B45F0-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B45DE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B45EB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B45EC-363D-11E5-9242-09173F13E4C5